Epithelial-Mesenchymal Transition Phenotype, Metformin, and Survival for Colorectal Cancer Patients with Diabetes Mellitus II
Objectives. We aimed to explore the association between metformin treatment and epithelial-mesenchymal transition (EMT) phenotype and further appraise the prognostic values of metformin and EMT markers E-cadherin and vimentin for colorectal cancer (CRC) in clinical practice. Methods. We collected sp...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2017-01-01
|
| Series: | Gastroenterology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2017/2520581 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832561055203590144 |
|---|---|
| author | Yaodu Wang Zhiyang Wu Likuan Hu |
| author_facet | Yaodu Wang Zhiyang Wu Likuan Hu |
| author_sort | Yaodu Wang |
| collection | DOAJ |
| description | Objectives. We aimed to explore the association between metformin treatment and epithelial-mesenchymal transition (EMT) phenotype and further appraise the prognostic values of metformin and EMT markers E-cadherin and vimentin for colorectal cancer (CRC) in clinical practice. Methods. We collected specimens and evaluated clinicopathological parameters of 102 stage I to III CRC patients with prediagnosed type 2 diabetes mellitus (DM II). Expression of E-cadherin and vimentin in tumors was detected by immunohistochemistry (IHC), and statistical analysis was performed using SPSS 19.0. Results. In correlation tests, we found a lower tumor cell EMT degree (more E-cadherin (P=0.014) and less vimentin (P=0.011) expression in patients who used metformin, and the expression of E-cadherin and vimentin was associated with serum CA19-9 (P=0.048, P=0.009), tumor invasive depth (T) (P<0.001, P=0.045), and lymph invasion (N) (P=0.013, P=0.001). In Cox multivariate regression analysis, E-cadherin was identified as a prognostic factor for disease-free survival (DFS) (P=0.038) and metformin use (P=0.015P=0.044) and lymph invasion (P=0.016P=0.023) were considered as the prognostic factors for both DFS and overall survival (OS). Conclusion. Our study suggested that metformin may impede the EMT process and improve survival for stage I–III CRC patients with DM II. |
| format | Article |
| id | doaj-art-fe94798744b14268b04f0b71ae2d865c |
| institution | Kabale University |
| issn | 1687-6121 1687-630X |
| language | English |
| publishDate | 2017-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Gastroenterology Research and Practice |
| spelling | doaj-art-fe94798744b14268b04f0b71ae2d865c2025-02-03T01:26:08ZengWileyGastroenterology Research and Practice1687-61211687-630X2017-01-01201710.1155/2017/25205812520581Epithelial-Mesenchymal Transition Phenotype, Metformin, and Survival for Colorectal Cancer Patients with Diabetes Mellitus IIYaodu Wang0Zhiyang Wu1Likuan Hu2Cancer Center, Shandong University Qilu Hospital, West Wenhua Road 107, Jinan, Shandong Province 250012, ChinaIntensive Care Unit, Shandong University Qilu Hospital (Qingdao), Hefei Road 758, Qingdao, Shandong Province 266035, ChinaCancer Center, Shandong University Qilu Hospital, West Wenhua Road 107, Jinan, Shandong Province 250012, ChinaObjectives. We aimed to explore the association between metformin treatment and epithelial-mesenchymal transition (EMT) phenotype and further appraise the prognostic values of metformin and EMT markers E-cadherin and vimentin for colorectal cancer (CRC) in clinical practice. Methods. We collected specimens and evaluated clinicopathological parameters of 102 stage I to III CRC patients with prediagnosed type 2 diabetes mellitus (DM II). Expression of E-cadherin and vimentin in tumors was detected by immunohistochemistry (IHC), and statistical analysis was performed using SPSS 19.0. Results. In correlation tests, we found a lower tumor cell EMT degree (more E-cadherin (P=0.014) and less vimentin (P=0.011) expression in patients who used metformin, and the expression of E-cadherin and vimentin was associated with serum CA19-9 (P=0.048, P=0.009), tumor invasive depth (T) (P<0.001, P=0.045), and lymph invasion (N) (P=0.013, P=0.001). In Cox multivariate regression analysis, E-cadherin was identified as a prognostic factor for disease-free survival (DFS) (P=0.038) and metformin use (P=0.015P=0.044) and lymph invasion (P=0.016P=0.023) were considered as the prognostic factors for both DFS and overall survival (OS). Conclusion. Our study suggested that metformin may impede the EMT process and improve survival for stage I–III CRC patients with DM II.http://dx.doi.org/10.1155/2017/2520581 |
| spellingShingle | Yaodu Wang Zhiyang Wu Likuan Hu Epithelial-Mesenchymal Transition Phenotype, Metformin, and Survival for Colorectal Cancer Patients with Diabetes Mellitus II Gastroenterology Research and Practice |
| title | Epithelial-Mesenchymal Transition Phenotype, Metformin, and Survival for Colorectal Cancer Patients with Diabetes Mellitus II |
| title_full | Epithelial-Mesenchymal Transition Phenotype, Metformin, and Survival for Colorectal Cancer Patients with Diabetes Mellitus II |
| title_fullStr | Epithelial-Mesenchymal Transition Phenotype, Metformin, and Survival for Colorectal Cancer Patients with Diabetes Mellitus II |
| title_full_unstemmed | Epithelial-Mesenchymal Transition Phenotype, Metformin, and Survival for Colorectal Cancer Patients with Diabetes Mellitus II |
| title_short | Epithelial-Mesenchymal Transition Phenotype, Metformin, and Survival for Colorectal Cancer Patients with Diabetes Mellitus II |
| title_sort | epithelial mesenchymal transition phenotype metformin and survival for colorectal cancer patients with diabetes mellitus ii |
| url | http://dx.doi.org/10.1155/2017/2520581 |
| work_keys_str_mv | AT yaoduwang epithelialmesenchymaltransitionphenotypemetforminandsurvivalforcolorectalcancerpatientswithdiabetesmellitusii AT zhiyangwu epithelialmesenchymaltransitionphenotypemetforminandsurvivalforcolorectalcancerpatientswithdiabetesmellitusii AT likuanhu epithelialmesenchymaltransitionphenotypemetforminandsurvivalforcolorectalcancerpatientswithdiabetesmellitusii |